Epicrispr Biotechnologies
PrivateLast Round
Series C
Aug 11, 2026
Est. Valuation
$95.14M
Total Funding Raised
$213M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Epicrispr Biotechnologies is a biotechnology company developing gene-modulating therapies using its proprietary Gene Expression Modulation System (GEMS) to treat a range of genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epicrispr Biotechnologies Comparables
Compare Epicrispr Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tune Therapeutics | 84% | |
| Moonwalk Biosciences | 84% | |
| Chroma Medicine | 83% |
Epicrispr Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 11, 2026 | ||||
| Series B | Mar 26, 2025 | ||||
| Series A | Jul 12, 2022 |
Epicrispr Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C |
| Horizons Ventures | Series A |
| abrdn Inc. | Series C |
| Ally Bridge Group | Series B |
| Readout Capital | Series C |
| Cormorant Asset Management | Series C |
| Duquesne Family Office | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 43% MoM.
- Sep 3, 2026
Grew 18% QoQ, from 44 to 52 employees.
Recent news
Latest coverage and updates
- is_developingAug 11, 2026
Epicrispr Biotechnologies, Inc. is developing epigenetic medicine for facioscapulohumeral muscular dystrophy on Apr 1st '26.
- receives_financingAug 11, 2026
Epicrispr Biotechnologies, Inc. closed $90M Series C financing in California on Aug 12th '26
- hiresAug 11, 2026
Epicrispr Biotechnologies, Inc. hires Anran Li as board.
Epicrispr Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Epicrispr Biotechnologies's valuation, stock price, and market status.
Is Epicrispr Biotechnologies a public or private company?
Epicrispr Biotechnologies is a private company.
What is the current stock price of Epicrispr Biotechnologies?
Epicrispr Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Epicrispr Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epicrispr Biotechnologies worth (valuation)?
Epicrispr Biotechnologies's valuation is estimated at $95.1M based on funding round data.
Can I buy Epicrispr Biotechnologies stock?
Epicrispr Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epicrispr Biotechnologies's last funding round?
Epicrispr Biotechnologies's most recent funding round was Series C on August 11, 2026.
Who are the main investors in Epicrispr Biotechnologies?
Key investors in Epicrispr Biotechnologies include Janus Henderson Group, Horizons Ventures, Ally Bridge Group, Octagon Capital Advisors.
Will Epicrispr Biotechnologies IPO soon?
No public IPO plans have been announced for Epicrispr Biotechnologies.
How can I track Epicrispr Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Epicrispr Biotechnologies's shares on secondary markets.